Specialties
Reports that name this provider
- Clinical Trial Access in Germany
- Participates in EU's first psilocybin compassionate use program for treatment-resistant depression, approved July 2025, in partnership with Filament Health
- Ibogaine Treatment Legality in Germany
- Operates EU's first psilocybin compassionate use programme approved by BfArM in July 2025
- Medication Availability in Germany
- Licensed to administer psilocybin under compassionate use program for treatment-resistant depression since July 2025
- Psilocybin Treatment Legality in Germany
- Private psychiatric day clinic co-founded by Dr. Andrea Jungaberle and Dr. Henrik Jungaberle. Closely associated with MIND Foundation for psychedelic research. Uses integrative model with virtual reality-assisted psychotherapy and somatic psychiatry
- Psychedelic Treatment Quality in Germany
- BfArM-authorized compassionate use psilocybin facility since July 2025; founded February 2021, expanded to full day clinic March 2024; led by Dr. Andrea Jungaberle; only non-university German institution authorized as study center for psychedelic drug approval pathways; bilingual German/English operation; maintains interdisciplinary team including anesthesiologists and emergency medicine specialists